Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.
Sibylle LoiblFrederic MarméMiguel MartinMichael UntchHervé R BonnefoiSung-Bae KimHarry BearNicole McCarthyMireia Melé OlivéKaren GelmonJosé García-SáenzCatherine M KellyToralf ReimerMasakazu ToiHope S RugoCarsten DenkertMichael GnantAndreas MakrisMaria KoehlerCynthia Huang-BartelettMaria Jose Lechuga FreanMarco ColleoniGustavo WerutskySabine SeilerNicole BurchardiValentina NekljudovaGunter von MinckwitzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Palbociclib for 1 year in addition to ET did not improve iDFS in women with residual invasive disease after NACT.